Literature DB >> 12883660

Differential expression of neuropilin-1 in malignant and benign prostatic stromal tissue.

Peter J Vanveldhuizen1, Muhammad Zulfiqar, Snigdha Banerjee, Rachel Cherian, Neela K Saxena, Amy Rabe, J Brantley Thrasher, Sushanta K Banerjee.   

Abstract

Neuropilin-1 (NRP-1), a co-receptor for VEGF165, is overexpressed in various prostate cancer cell lines and in advanced prostate tumors. However, distribution of the NRP-1 in prostate tumors has not yet been evaluated. Using immunohistochemical analysis, we evaluated 21 archival prostate tumors and 5 benign glands for the expression of NRP-1. In addition, we utilized a quantitative RT-PCR method to examine mRNA expression in 9 additional prostate tumors obtained from radical prostatectomy specimens and compared this expression to the adjacent normal tissue. The RT-PCR analyses demonstrated overexpression of NRP-1 mRNA in malignant tissue samples by 10.0-fold as compared to adjacent normal tissue. By immunohistochemistry, NRP-1 protein was undetected or minimally detected in the epithelial tumor cells. However, NRP-1 immuno-reaction was detected in the surrounding tumor stroma. Variable immuno-reaction for NRP-1 was also seen in the adjacent normal tumor stroma and the stroma of the benign prostate samples. These observations suggest that neuropilin-1 is expressed in the prostatic stromal cells, not epithelial tumor cells, and this expression is significantly increased in the malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883660

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  10 in total

Review 1.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  Sina Koch; Lena Claesson-Welsh
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.

Authors:  Sonja Loges; Thomas Schmidt; Peter Carmeliet
Journal:  Genes Cancer       Date:  2010-01

Review 3.  Neuropilins: expression and roles in the epithelium.

Authors:  Jonathan R L Wild; Carolyn A Staton; Keith Chapple; Bernard M Corfe
Journal:  Int J Exp Pathol       Date:  2012-04       Impact factor: 1.925

4.  VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors.

Authors:  D Grun; G Adhikary; R L Eckert
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

Review 5.  VEGF targets the tumour cell.

Authors:  Hira Lal Goel; Arthur M Mercurio
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

6.  Peritumoral Neuropilin-1 and VEGF receptor-2 expression increases time to recurrence in hepatocellular carcinoma patients undergoing curative hepatectomy.

Authors:  Peng-Yuan Zhuang; Jian-Dong Wang; Zhao-Hui Tang; Xue-Ping Zhou; Yong Yang; Zhi-Wei Quan; Ying-Bin Liu; Jun Shen
Journal:  Oncotarget       Date:  2014-11-30

7.  MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.

Authors:  Enrica Vescarelli; Giulia Gerini; Francesca Megiorni; Eleni Anastasiadou; Paola Pontecorvi; Luciana Solito; Claudia De Vitis; Simona Camero; Claudia Marchetti; Rita Mancini; Pierluigi Benedetti Panici; Carlo Dominici; Ferdinando Romano; Antonio Angeloni; Cinzia Marchese; Simona Ceccarelli
Journal:  J Exp Clin Cancer Res       Date:  2020-01-02

8.  Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420.

Authors:  Smita Mehta; James Moon; Mehmood Hashmi; Michael Leblanc; Chao Hui Huang; Elizabeth Rinehart; Gregory T Wolf; Susan G Urba; Sushanta K Banerjee; Stephen Williamson
Journal:  Oncol Rep       Date:  2013-04-02       Impact factor: 3.906

9.  Neuropilins: a new target for cancer therapy.

Authors:  Camille Grandclement; Christophe Borg
Journal:  Cancers (Basel)       Date:  2011-04-08       Impact factor: 6.639

Review 10.  Pazopanib and anti-VEGF therapy.

Authors:  Harry A Drabkin
Journal:  Open Access J Urol       Date:  2010-03-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.